Linear IgA bullous dermatosis Management

Linear IgA bullous dermatosis

Linear IgA bullous dermatosis (LABD) is a rare chronic autoimmune blistering disease characterized by the formation of tense vesicles and bullae involving the skin and, in some patients, the mucous membranes. The disease results from linear deposition of immunoglobulin A (IgA) along the basement membrane zone, causing separation of the epidermis from the dermis and blister formation.

Linear IgA bullous dermatosis occurs in both children and adults. In children, it is often referred to as chronic bullous disease of childhood. The disease may occur spontaneously or be triggered by certain medications, particularly vancomycin. Most patients respond well to treatment, although relapses may occur.

Pathophysiology (Brief)

The main mechanism is autoantibody-mediated injury of the basement membrane zone.

IgA antibodies are deposited linearly along the dermoepidermal junction, leading to:

• Activation of neutrophils

• Inflammation of the basement membrane

• Separation of the epidermis from the dermis

• Formation of subepidermal vesicles and bullae

Some cases are associated with:

• Drug exposure (especially vancomycin)

• Autoimmune diseases

• Inflammatory bowel disease

• Malignancy (rare)

Signs & Symptoms

Typical lesions include:

• Tense vesicles and bullae

• Intensely itchy skin lesions

• Annular or grouped blisters

• New blisters forming around older lesions ("cluster of jewels" appearance), particularly in children

Common sites:

• Trunk

• Lower abdomen

• Groin

• Perineum

• Buttocks

• Limbs

Mucosal involvement may include:

• Oral ulcers

• Eye involvement

• Genital lesions

Other findings:

• Lesions heal with minimal scarring

• Secondary bacterial infection may occur

• Chronic relapsing course

Diagnostic Criteria

Diagnosis is based on:

• Characteristic tense vesicles and bullae

• Clinical distribution of lesions

• Histopathological findings

• Linear IgA deposition along the basement membrane on direct immunofluorescence, which confirms the diagnosis

Investigations

Recommended investigations

• Skin biopsy

• Full blood picture (FBP)

• Liver function tests (LFTs)

• Renal function tests (RFTs)

Special investigations

• Direct immunofluorescence (gold standard)

• Indirect immunofluorescence where available

Monitoring

During prolonged immunosuppressive therapy monitor:

• Full blood count

• Liver function

• Renal function

• Blood glucose in patients receiving corticosteroids

• Glucose-6-phosphate dehydrogenase (G6PD) status before initiating dapsone where available

Treatment

Treatment aims to suppress inflammation, promote healing of skin lesions, relieve itching, and prevent disease recurrence.

Non-pharmacological Treatment

• Maintain good skin hygiene.

• Protect intact blisters from trauma.

• Use non-adherent dressings for eroded skin.

• Identify and discontinue any suspected causative medication, particularly vancomycin.

• Maintain adequate nutrition and hydration.

• Treat secondary bacterial infections promptly.

• Regular follow-up to monitor disease activity and treatment adverse effects.

Pharmacological Treatment

• Betamethasone cream/ointment (topical) — apply every 12 hours until improvement.

OR

• Clobetasol propionate cream/ointment (topical) 0.05% — apply every 12 hours until improvement.

AND

• Prednisolone (PO) 0.5–1 mg/kg once daily for 2 months, then gradually taper to the lowest effective dose.

AND (for extensive involvement)

• Methotrexate (PO) 7.5–20 mg once weekly for not less than 4 months

OR (steroid-sparing alternatives, specialist level):

• S: Methotrexate (PO) 10–15 mg once weekly for at least 4 months with folic acid.

• OR S: mycophenolate mofetil (PO) 1 g/day for at least 4 months.

• OR S: rituximab (IV) 375 mg/m² weekly for 4 weeks.

Additional treatment

• Dapsone (PO) 100 mg once daily may be considered in selected patients under specialist supervision, particularly where corticosteroid-sparing therapy is required.

Complications

• Secondary bacterial skin infection

• Painful skin erosions

• Eye involvement, which may result in visual impairment if untreated

• Scarring of mucosal surfaces

• Adverse effects of prolonged corticosteroid or immunosuppressive therapy

• Disease relapse

Prevention

There is no known method of preventing linear IgA bullous dermatosis. However, recurrence and complications may be reduced by:

• Early diagnosis and treatment

• Avoiding medications known to trigger the disease

• Regular clinical follow-up

• Prompt treatment of secondary infections

• Careful monitoring during immunosuppressive therapy

Patient counselling (Important)

• Linear IgA bullous dermatosis is an autoimmune disease and is not contagious.

• Treatment often requires several months, and relapses may occur.

• Do not stop corticosteroids or immunosuppressive medicines without medical advice.

• Inform your healthcare provider if a new medication was started before the rash developed.

• Seek immediate medical attention if eye pain, visual changes, difficulty swallowing, or extensive blistering occurs.